THE EFFICACY AND SAFETY OF THE NEW DRUG FISSARIO IN CLINICAL USAGE FOR THE TOPICAL TREATMENT OF THE ACUTE ANAL FISSURE ASSOCIATED WITH CHRONIC HEMORRHOID DISEASE

AIM. To prove primary efficiency of Fissario in comparison with RelifAdvansfor anal fissure therapy and to confirm previously received safety data. MATERIAL AND METHODS. Multicenter, open, randomized, comparative clinical trial in parallel groups with active control (RelifAdvans) was conducted at 18 clinical centers in Russia, 188 patients participated.. Patients with deep and superficial analfissure in combination with chronic hemorrhoids were eligible for participation in trial. Patients administered investigational drugs 2 times a day for 28 days. Efficacy primary endpoint assessed as part ofpatients withfull healing of analfissure and epithelization on Day 28 from start of therapy. Also pharmacokinetics research was performed.: concentration of Nifedipinein blood plasma was assessed. Safety assessment was performed based on frequency and character of registered adverse events. RESULTS. Efficacy analysis showed statistically significant differences in favor of investigational drug in comparison with comparator on efficacy primary endpoint -part of patients with healing of anal fissure at Day 28. Difference of parts of defendants between group of investigational drug and comparator in full data population (with replacement of missed data) was 24,5 % (two-sided confidence interval 95 % for a difference of parts [11,9; 37,0 %], р <0,001), ratio of parts 1,4. Pharmacokinetics analysis based on Nifedipine concentration in plasma showed that observed concentration of Nifedipine in plasma after single rectal and topical use are significantly lower than therapeutic range. Most common adverse events registered during trial were gastrointestinal tract reactions and reactions at investigational drug application site. No serious adverse events, no serious unexpected adverse drug reactions nor cases of death were registered during trial. No influence of Fissario on results of clinical blood tests, biochemical blood tests, general urinalysis and ECG were registered during trial. CONCLUSION. Fissario, ointment for rectal and topical use, is an effective and safe drug for local therapy of acute anal fissure in combination with a chronic hemorrhoids. Fissario achieved more than 40 % superiority in comparison with Relif Advans based on anal fissure epithelizationrate at Day 28 of treatment.

Fissario, analfissure, hemorrhoid, nifedipine, lidocaine, clinical trial

1. Экспертная комиссия Общероссийской Общественной Организации «Ассоциация колопроктологов России» // Клинические рекомендации по диагностике и лечению взрослых пациентов с анальной трещиной, М. - 2013.

2. Altomare, D.F. The management of patients with primary chronic anal fissure: a position paper / D.F.Altomare et al. // Tech. Coloproctol. - 2011. -№ 15, - с. 135-141.

3. Благодарный, Л.А. Медикаментозное лечение геморроя и анальной трещины / Л.А.Благодарный, Г.И.Воробьев // Фармацевтический вестник. Общая Колопроктология, М. - 2006. - т. 2. - № 1 -с. 34

4. Antropoli, C. Nifedipine for local use in conservative treatment of anal fissures: preliminary results of a multicenter study. / C.Antropoli, P.Perrotti, M.Rubino et al. // Dis. Colon Rectum. - 1999. - № Aug 42 (8). -с. 1011-5.

5. Перцев, И.М. Фармацевтические и медико-биологические аспекты лекарств. / И.М.Перцев, И.А.Зупанец // Харьков: Изд-во НФАУ; 1999. - т. 1.

6. Golfam, F. The effect of topical nifedipine in treatment of chronic anal fissure. / F.Golfam, P.Golfam, A.Khalaj et al. //Acta Med. Iran. - 2009. - № Sep-Oct 48 (5), - с. 295-9.

7. Katsinelos, P. Topical 0,5 % nifedipine vs. lateral internal sphincterotomy for the treatment of chronic anal fissure: long-term follow-up / P.Katsinelos et al.//Int. J. Colorectal. Dis 2006. - № 21. - с. 179-183

8. Perrotti, P. Pharmacokinetics of anorectalnifedipine and lidocaine (lignocaine) ointment following haem-orrhoidectomy: an open-label, single-dose, phase IV clinical study. / P.Perrotti, P.Dominici, E.Grossi et al. // Clin. Drug. Investig. - 2009. - № 29 (4). - с. 243-56.